These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22801065)

  • 1. Do novel biomarkers add to existing scores of total cardiovascular risk?
    De Backer G; Graham I; Cooney MT
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):14-7. PubMed ID: 22801065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The science of risk models.
    Prieto-Merino D; Pocock SJ
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):7-13. PubMed ID: 22801064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical validation of genetic markers for improved risk estimation.
    Kessler T; Schunkert H
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):25-32. PubMed ID: 22801067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.
    Zethelius B; Berglund L; Sundström J; Ingelsson E; Basu S; Larsson A; Venge P; Arnlöv J
    N Engl J Med; 2008 May; 358(20):2107-16. PubMed ID: 18480203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk.
    Bell K; Hayen A; McGeechan K; Neal B; Irwig L
    Eur J Prev Cardiol; 2012 Dec; 19(6):1474-85. PubMed ID: 21947629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of cardiovascular disease events.
    Wilson PW
    Cardiol Clin; 2011 Feb; 29(1):1-13. PubMed ID: 21257097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for treating lipids for prevention: risk stratification models with and without imaging.
    Okwuosa TM; Mallikethi-Reddy S; Jones DM
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):295-307. PubMed ID: 24840260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-guided therapy: a first step to personalized medicine.
    Zannad F; Koenig W
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):5-6. PubMed ID: 22801063
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar.
    Welsh P; Packard CJ; Sattar N
    Curr Opin Lipidol; 2008 Dec; 19(6):563-71. PubMed ID: 18957878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management.
    Gupta M; Singh N; Tsigoulis M; Kajil M; Hirjikaka S; Quan A; Teoh H; Verma S
    Can J Cardiol; 2012; 28(1):14-9. PubMed ID: 22264843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple biomarkers for the prediction of first major cardiovascular events and death.
    Wang TJ; Gona P; Larson MG; Tofler GH; Levy D; Newton-Cheh C; Jacques PF; Rifai N; Selhub J; Robins SJ; Benjamin EJ; D'Agostino RB; Vasan RS
    N Engl J Med; 2006 Dec; 355(25):2631-9. PubMed ID: 17182988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conclusion.
    Koenig W; Zannad F
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):54-5. PubMed ID: 22801070
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide.
    McGeechan K; Macaskill P; Irwig L; Liew G; Wong TY
    Arch Intern Med; 2008 Nov; 168(21):2304-10. PubMed ID: 19029492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Discriminative ability, reclassification and net benefit: the predictive value of biomarkers].
    Steyerberg EW; Pencina MJ; Van Calster B
    Ned Tijdschr Geneeskd; 2012; 156(41):A5029. PubMed ID: 23062255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender-based cardiometabolic risk evaluation in minority and non-minority men grading the evidence of non-traditional determinants of cardiovascular risk.
    Billups KL; Miner MM; Wierzbicki AS; Jackson G
    Int J Clin Pract; 2011 Feb; 65(2):134-47. PubMed ID: 21199197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should pulse pressure become part of the Framingham risk score?
    Nawrot TS; Staessen JA; Thijs L; Fagard RH; Tikhonoff V; Wang JG; Franklin SS
    J Hum Hypertens; 2004 Apr; 18(4):279-86. PubMed ID: 15037878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk prediction of incident coronary heart disease in The Netherlands: re-estimation and improvement of the SCORE risk function.
    Merry AH; Boer JM; Schouten LJ; Ambergen T; Steyerberg EW; Feskens EJ; Verschuren WM; Gorgels AP; van den Brandt PA
    Eur J Prev Cardiol; 2012 Aug; 19(4):840-8. PubMed ID: 21551214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
    Ridker PM
    J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.